Bisphosphonate vs Denosumab: Which Osteoporosis Treatment Is Right for You?

This article is a draft for editorial and qualified medical review. It has not yet received a documented physician review and should not be treated as finalized clinical guidance.

Bisphosphonates (alendronate, risedronate, ibandronate, and intravenous zoledronic acid) and denosumab (brand name Prolia, a subcutaneous RANKL-inhibiting monoclonal antibody) are both FDA-approved antiresorptive treatments for osteoporosis in postmenopausal women and, for some agents, in men and glucocorticoid-induced osteoporosis. Both classes reduce vertebral and hip fracture risk substantially compared with no treatment in pivotal randomized trials. The choice between them is not simply "which is stronger." It depends on kidney function, how confident the patient and prescriber are about long-term adherence to a follow-up plan, and whether the patient can tolerate the specific failure mode of each drug: gastrointestinal intolerance and rare atypical fractures with bisphosphonates, versus a well-documented rebound surge in fracture risk if denosumab is stopped without a bisphosphonate bridge. That last point is the single most consequential difference between the two classes and it is where prescribing decisions most often go wrong.

A note on sourcing before you read further: several identifiers attached to this topic's underlying trials in earlier drafts of this material could not be independently verified against the cited PubMed, NEJM, and JAMA links, and some links did not resolve to the paper they were said to support. Rather than repeat unverifiable citations, this revision names the pivotal trials by their established public identifiers (FREEDOM, HORIZON-PFT, FIT, VERT-NA, DECIDE, STAND, ARCH, STRUCTURE, ACTIVE, VERO) without attaching a specific link to each, and flags that a clinical reviewer should confirm exact effect sizes against the primary publications or current FDA labeling before this page is finalized.

What is established, what is plausible, and what is not established

Established from multiple randomized trials and reflected in current guideline recommendations: both bisphosphonates and denosumab reduce vertebral and hip fracture incidence in postmenopausal women with osteoporosis over 1 to 3 years of treatment, denosumab produces larger bone mineral density (BMD) gains than oral bisphosphonates at matched skeletal sites, and stopping denosumab without transitioning to a bisphosphonate is associated with rapid bone turnover rebound and clusters of multiple vertebral fractures in the following 12 to 18 months.

Plausible but not settled by head-to-head trial evidence: whether denosumab's larger BMD gains translate into a meaningfully lower long-term fracture rate than IV zoledronic acid, since no adequately powered head-to-head fracture-endpoint trial has directly compared the two; and the optimal timing and number of bisphosphonate bridging doses after stopping denosumab, which remains an area of active study rather than a fixed protocol.

Not established: the exact comparative cost-effectiveness of a 10-year denosumab course versus 10 years of generic alendronate in a US population is an evolving question rather than a settled number. A 2025 economic modeling analysis examined this comparison directly (PubMed 40588656); readers and reviewers should consult that paper directly rather than rely on a single quoted cost-per-outcome figure, since these models are sensitive to drug pricing assumptions that change over time.

How the two drug classes work

Bisphosphonates

Bisphosphonates are pyrophosphate analogs that bind to hydroxyapatite mineral on bone surfaces. When osteoclasts resorb bisphosphonate-coated bone, the drug is taken up into the cell and disrupts an internal metabolic pathway, driving osteoclast cell death. Because the drug is physically incorporated into bone mineral, it has a very long skeletal residence time, plausibly years, which is why bisphosphonates retain some antifracture effect for a period after the drug is stopped ("drug holiday").

Denosumab

Denosumab is a fully human monoclonal antibody that binds RANKL, the signaling protein osteoblasts use to activate osteoclast formation and survival. By blocking RANKL before it reaches its receptor, denosumab suppresses osteoclast activity. Unlike bisphosphonates, denosumab does not bind to bone mineral. It circulates in serum with a half-life on the order of a few weeks and clears from the body without leaving a skeletal reservoir. When serum levels fall after a missed or discontinued dose, RANKL signaling is no longer suppressed and osteoclast activity can rebound above pretreatment levels.

This mechanistic difference, mineral-bound residual protection versus no skeletal reservoir, is the reason the two drugs behave so differently when treatment stops, and it should be the starting point for any discussion of long-term treatment planning.

Fracture reduction: what the pivotal trials showed

Both drug classes have strong placebo-controlled fracture-endpoint evidence in postmenopausal women with osteoporosis.

• Denosumab's pivotal trial (FREEDOM) enrolled several thousand postmenopausal women with low bone density and reported substantial reductions in new vertebral fractures, a meaningful reduction in hip fractures, and a smaller but significant reduction in nonvertebral fractures over three years, compared with placebo. A long-term open-label extension followed a subset of participants for up to ten years without an apparent loss of antifracture effect.
• Zoledronic acid's pivotal trial (HORIZON-PFT) reported vertebral, hip, and nonvertebral fracture reductions of a similar magnitude to FREEDOM over three years, though the trials were run separately and cross-trial comparison has real limitations (different populations, follow-up periods, and fracture ascertainment methods).
• Oral alendronate (FIT) and risedronate (VERT-NA) also produced significant vertebral and hip fracture reductions in placebo-controlled trials, generally somewhat smaller in absolute terms than the IV zoledronic acid and denosumab trials, which may partly reflect the adherence challenges of daily or weekly oral dosing rather than a true efficacy gap.

Exact percentage figures for each trial are widely cited in guideline documents, but this draft avoids repeating specific numbers without a verified citation. A reviewing clinician should confirm current effect-size figures against the FDA label, the original trial publication, or a current systematic review before those numbers are published.

Where denosumab and bisphosphonates diverge on BMD

Direct comparison trials (DECIDE, comparing denosumab against alendronate, and STAND, examining patients switched from alendronate to denosumab) reported larger increases in hip and spine BMD with denosumab than with continued oral alendronate over 12 months. Long-term extension data suggest denosumab's BMD gains continue accruing for at least a decade without an obvious plateau, while oral bisphosphonates typically plateau within three to five years.

BMD is a surrogate marker used by regulators and guideline bodies to track treatment response; it is not itself the outcome that matters to a patient. A larger BMD gain does not automatically prove a proportionally larger fracture-risk reduction, since the two classes work through different mechanisms and no trial has fully isolated BMD change as the sole driver of denosumab's antifracture benefit.

Decision-relevant comparison table

This table reflects general patterns from the trials and safety literature described above and from bone specialty society position statements on denosumab discontinuation. It is not a substitute for an individualized decision made with a prescriber who has reviewed the patient's DXA results, kidney function, dental history, and fracture history.

The denosumab discontinuation problem

This is the point in the comparison that most changes the initial-choice decision. Once denosumab is started, its serum-based mechanism means there is no mineral reservoir left behind when it is stopped. Position statements from bone specialty societies (including a widely cited systematic review and position statement from the European Calcified Tissue Society) describe bone turnover markers rising above pretreatment baseline within roughly three to six months of the last dose, meaningful BMD loss at the spine within the first year off therapy, and case series describing multiple vertebral compression fractures occurring in a single patient within 7 to 18 months of stopping. Patients who were on denosumab longest and those who already had a vertebral fracture before starting appear to carry the highest rebound risk.

The generally recommended approach, described in the same position statements, is to give a bisphosphonate, most commonly a single IV zoledronic acid dose, within about six months of the final denosumab injection, followed by DXA and bone turnover marker rechecks to confirm the rebound has been blunted. Even with this bridge, some patients still lose meaningful bone density, which is why the decision to start denosumab should include a discussion of who will be responsible for making sure the transition actually happens, not just what to do if it is stopped.

Kidney function is a clear differentiator

Bisphosphonates are cleared renally, and both alendronate/risedronate and zoledronic acid carry cautions or contraindications in more advanced kidney impairment; zoledronic acid specifically carries an FDA warning related to acute kidney injury risk, particularly with dehydration or pre-existing renal disease, so serum creatinine is typically checked before each annual infusion.

Denosumab is cleared through the reticuloendothelial system rather than the kidneys, so it does not carry the same renal-function cutoff, and this is one of the most common reasons prescribers choose it over a bisphosphonate in patients with chronic kidney disease. That does not make denosumab risk-free in this population: patients with more advanced CKD (roughly eGFR under 30) are at meaningfully higher risk of severe and sometimes prolonged hypocalcemia after a denosumab injection and need calcium, phosphorus, and vitamin D monitoring around each dose.

Side effects: different failure modes, not simply "more or less safe"

Oral bisphosphonates commonly cause esophageal or upper GI irritation, which combined with the strict administration instructions is a major driver of real-world discontinuation. Denosumab has no comparable GI burden. Both classes carry a small but real risk, generally reported to rise with cumulative duration of use beyond about five years, of two rare but serious events: atypical femoral fracture (which can present as unusual thigh or groin pain, sometimes before an actual fracture occurs, and warrants urgent orthopedic evaluation) and osteonecrosis of the jaw (exposed bone in the mouth that fails to heal, usually after a dental extraction or invasive dental procedure, which warrants urgent dental and often oral surgery evaluation). Neither risk is unique to one drug class, and dental clearance before starting either type of therapy is a reasonable precaution, particularly for patients anticipating dental extractions or implants.

Choosing within the bisphosphonate class: oral versus IV

Zoledronic acid appears to be the more potent bisphosphonate on fracture-endpoint trial evidence and offers the adherence advantage of once-yearly dosing, at the cost of an acute-phase reaction (fever, myalgia, joint aches in the day or two after the first infusion) in a substantial minority of first-time recipients, which is usually self-limited and manageable with acetaminophen and typically does not recur with later infusions. Persistence with oral bisphosphonates in real-world cohorts is commonly reported to be poor at one year, which is one of the practical reasons a prescriber may favor the IV option for a patient who has previously struggled with a daily or weekly pill regimen, or reasonable generic-cost oral therapy for a patient who tolerates it and wants to minimize cost.

Where anabolic agents fit in the sequencing decision

Bisphosphonates and denosumab are both antiresorptive; they slow bone breakdown. A separate class of FDA-approved drugs, teriparatide (Forteo), abaloparatide (Tymlos), and romosozumab (Evenity), builds new bone. Teriparatide and abaloparatide are parathyroid hormone or PTH-related protein analogs given as daily subcutaneous injections, generally for up to roughly two years given cumulative-exposure limits in their labeling. Romosozumab is a sclerostin-inhibiting antibody with a dual formation-and-antiresorptive mechanism, given for a defined 12-month course, and it carries an FDA boxed warning for cardiovascular risk; it is not appropriate for patients with a myocardial infarction or stroke in the preceding year.

Current guideline recommendations from endocrine specialty societies describe an "anabolic first" approach for patients judged to be at very high fracture risk, for example those with a recent fragility fracture, a very low T-score, or a fracture that occurred while already on antiresorptive therapy: a period of anabolic therapy followed by transition to a bisphosphonate or denosumab for long-term maintenance. A head-to-head trial (VERO) comparing teriparatide against risedronate in patients with severe osteoporosis reported a substantially lower new vertebral fracture rate with the anabolic-first sequence, though the exact effect size in that trial should be confirmed against the original publication before being quoted precisely. This is a guideline recommendation built on trial evidence, not a claim that anabolic therapy is appropriate for every osteoporosis patient; most patients starting osteoporosis treatment are not in the "very high risk" category that this sequencing recommendation targets.

Earlier drafts of comparison material on this topic attributed direct quotations to named specialists and to a specialty society regarding this treatment sequence. Those quotations could not be verified against a citable source and have been removed rather than repeated as attributed statements; the underlying guideline recommendation about anabolic-first sequencing for very-high-risk patients is retained because it reflects a documented position of endocrine specialty guidelines, described here in paraphrase rather than quotation.

A decision framework

No single factor decides between a bisphosphonate and denosumab. In practice, five questions tend to drive the decision:

1. How severe is the current fracture risk? Patients with a recent fragility fracture or very low T-score may be better served starting with an anabolic agent before either antiresorptive is chosen for maintenance.
2. What is kidney function? Reduced renal function pushes toward denosumab; normal renal function keeps both options open.
3. Can the patient realistically commit to years of injections and to a formal discontinuation plan if therapy is later stopped? If not, a bisphosphonate with a residual effect and the option of a drug holiday may be the safer default.
4. What is the adherence pattern likely to be? Poor tolerance of oral regimens favors IV zoledronic acid or denosumab over daily or weekly pills.
5. What does cost and coverage look like for this patient right now? Generic oral bisphosphonates are substantially less expensive than denosumab at list price; the newer cost-effectiveness literature on 10-year denosumab versus alendronate should be checked directly for current figures rather than relied on from memory (PubMed 40588656).

Monitoring, whichever drug is chosen

Guideline-based monitoring generally involves a repeat DXA scan roughly two years after starting therapy, with earlier reassessment if there is a new fracture or a reason to suspect non-adherence or secondary bone loss. A meaningful BMD decline on treatment (commonly described as around 5% or more at the spine, or around 4% or more at the hip) should prompt investigation for secondary causes, malabsorption in patients on oral bisphosphonates, or missed doses rather than an assumption that the drug has simply failed. Serum CTX, a bone resorption marker, can help confirm that an antiresorptive is having a biological effect within a few months of starting; P1NP is more commonly used to track response to anabolic therapy. For bisphosphonates, reassessment for a possible drug holiday is typically considered around year 3 for IV zoledronic acid and year 5 for oral agents, with ongoing monitoring during any pause. For denosumab, the equivalent reassessment point is not a holiday decision but a transition-planning decision: when should a bisphosphonate be introduced, and how will the transition be confirmed with follow-up labs and imaging.

When to seek urgent care rather than wait for a routine visit

New, unexplained thigh or groin pain in a patient on long-term bisphosphonate or denosumab therapy warrants prompt evaluation for a possible atypical femoral fracture rather than being dismissed as musculoskeletal strain. Exposed bone in the mouth that does not heal, especially after a dental extraction, warrants prompt dental or oral surgery evaluation for possible osteonecrosis of the jaw. A patient who has missed or is planning to stop denosumab injections without having discussed a bisphosphonate transition with their prescriber should contact that prescriber before simply stopping, given the documented rebound fracture risk.

References

• 2025 cost-effectiveness modeling of 10-year denosumab versus alendronate in postmenopausal osteoporosis, United States: https://pubmed.ncbi.nlm.nih.gov/40588656/
• FDA drug label and safety information pages (denosumab/Prolia, zoledronic acid, alendronate, teriparatide, abaloparatide, romosozumab): https://www.fda.gov
• Registered and completed osteoporosis treatment trials, for verifying specific trial names and outcomes referenced above (FREEDOM, HORIZON-PFT, FIT, VERT-NA, DECIDE, STAND, ARCH, STRUCTURE, ACTIVE, VERO): https://clinicaltrials.gov